Q1 2026 trends point to AI, new therapies and policy shifts in sleep medicine

Recent developments across technology, therapeutics, policy, and public health point to several themes shaping the practice of sleep medicine in early 2026. Artificial intelligence continues to appear across clinical research, consumer health tools, and regulatory activity, while treatment options continue to expand. Policy developments remain a key consideration for sleep medicine practices, and sleep continues to feature prominently in public health discussions.

Consumer technology plays a larger role in health monitoring. Large technology companies continue to integrate sleep-related features into consumer health ecosystems, often positioning sleep data as part of broader wellness monitoring. Samsung, for example, has emphasized sleep apnea risk identification through Galaxy Watch data, while Microsoft has introduced Copilot Health as a consumer-facing AI tool that can synthesize health information and support care planning. Retail and technology platforms, including Amazon One Medical, are broadening digital health services. Although these offerings are not tailored to sleep care, they can influence the pathways through which patients seek evaluation for sleep-related symptoms.

Artificial intelligence is applied across multiple settings. In research settings, Mayo Clinic investigators are using AI-enabled ECG analysis to detect obstructive sleep apnea, while Stanford Medicine researchers have developed an AI-driven model that uses a single night of physiological sleep data to predict the risk of more than 100 health conditions. Beyond research and care delivery, AI is being incorporated into regulatory processes. The FDA has announced plans to use agentic AI to support premarket review and post-market surveillance activities, signaling broader adoption of these tools in evaluating devices and therapies.

Treatment options continue to expand. Progress in oral therapies for obstructive sleep apnea, including candidates from companies such as Apnimed and Incannex, reflects continued interest in alternatives to positive airway pressure. At the same time, the FDA has taken multiple actions related to narcolepsy treatments, including approvals, priority reviews, and breakthrough designations for orexin-targeting therapies.

Device-based treatments are also evolving. The FDA’s premarket approval of LivaNova’s aura6000 hypoglossal nerve stimulation system and clearance of the Naox Link in-ear EEG device illustrate continued diversification of both therapeutic and diagnostic tools. Updates to FDA guidance on wellness devices further support the growth of wearables and at-home monitoring technologies.

Sleep apnea and weight management remain closely linked. Retail pharmacies such as Amazon Pharmacy and Walgreens are expanding access to GLP1 medications through home delivery and virtual weight management clinics, while platforms like Walmart’s Better Care Services connect patients to third-party providers and prescription programs. These developments have implications for sleep clinicians, as weight-loss therapies are increasingly part of care conversations for patients with obstructive sleep apnea. At the same time, industry warnings about compounded medications and emerging research on potential risks, such as osteoporosis and gout, underscore the need for coordinated care and careful patient counseling. New clinician and patient resources on obesity management were also introduced to support care discussions related to sleep apnea and weight.

Policy and reimbursement issues affect daily practice. CMS has announced new HCPCS codes for hypoglossal nerve stimulation procedures and convened stakeholders to address administrative burden across health care. Congress has extended several Medicare telehealth flexibilities through 2027, while payer policies related to remote monitoring and prior authorization continue to evolve. Together, these updates reflect ongoing efforts to adapt coverage and reimbursement frameworks to newer technologies and care models, with direct implications for practice operations and patient access.

Sleep health remains a public health focus. Data released in March show ongoing gaps in sleep duration and understanding of sleep needs among children and adolescents, prompting the National Sleep Foundation to issue adolescent sleep health recommendations. Adult sleep behaviors are also in focus, with a survey showing widespread use of sleep tracking devices and growing concern about screen use at bedtime. These findings reinforce the role of sleep medicine within broader prevention and population health conversations.